21 June 2024 - Recommendations made by the PBAC in May 2024 relating to the listing of medicines on the PBS and vaccines on the NIP are now available.

The outcomes are as follows:

• Aflibercept (Eylea) for age-related macular degeneration - recommendation (lowest cost alternative)
• Aflibercept (Eylea) for diabetic macular oedema - recommendation (lowest cost alternative)
• Foslevodopa with foscarbidopa (Vyalev) for Parkinson's disease - rejection (uncertain clinical benefit)
• Respiratory syncytial virus vaccine (bivalent) (Abrysvo) for vaccination against RSV infection - recommendation (price reduction required) 

The PBAC also reviewed/considered:

• Listings for two medicines for patients with attention deficit hyperactivity disorder
• Its March 2024 recommendation for migalastat hydrochloride (Galafold) for Fabry disease
• Listings for multiple brands of somatropin for patients with late-onset growth hormone deficiency

Items for nurse practitioner and endorsed midwife prescribing

Read PBS News